Modality
Vaccine
MOA
FGFRi
Target
JAK1
Pathway
Checkpoint
ACCLN
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
Nov 2017
→ Dec 2028
Phase 3Current
NCT07432264
2,360 pts·LN
2021-07→2026-05·Active
NCT03972083
1,213 pts·LN
2017-11→2028-12·Recruiting
NCT07060885
955 pts·ACC
2024-06→2026-11·Active
+1 more trial
7,394 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-05-272mo awayPh3 Readout· LN
2026-11-077mo awayPh3 Readout· ACC
2028-01-271.8y awayPh3 Readout· LN
2028-12-092.7y awayPh3 Readout· LN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Recruit…
P3
Active
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2026-05-27 · 2mo away
LN
Ph3 Readout
2026-11-07 · 7mo away
ACC
Ph3 Readout
2028-01-27 · 1.8y away
LN
Ph3 Readout
2028-12-09 · 2.7y away
LN
RecruitingActive|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07432264 | Phase 3 | LN | Active | 2360 | CfB |
| NCT03972083 | Phase 3 | LN | Recruiting | 1213 | HAM-D |
| NCT07060885 | Phase 3 | ACC | Active | 955 | PANSS |
| NCT05295043 | Phase 3 | LN | Recruiting | 2866 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| MLY-3531 | Mineralys | NDA/BLA | JAK1 |